{"id":58309,"date":"2026-02-09T13:38:24","date_gmt":"2026-02-09T11:38:24","guid":{"rendered":"https:\/\/pulsenmore.com\/?p=58309"},"modified":"2026-03-31T12:42:34","modified_gmt":"2026-03-31T09:42:34","slug":"pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance","status":"publish","type":"post","link":"https:\/\/pulsenmore.com\/es\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/","title":{"rendered":"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

OMER, Israel, Feb. 9, 2026 \/PRNewswire\/<\/b><\/span> \u2013 Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women\u2019s ultrasound practice in Maryland, as part of its growing U.S. rollout.<\/span><\/span><\/span><\/p>

In early February 2026, Pulsenmore, through its U.S. subsidiary, entered into a services agreement with TLC Perinatal PA, which operates in Silver Spring and Germantown, Maryland. Under the agreement, TLC Perinatal will incorporate Pulsenmore\u2019s Early Screening (ES) home ultrasound services into its care model, allowing patients to perform ultrasound scans at home as part of a physician-directed hybrid care pathway that incorporates telehealth and scheduled in-clinic visits.<\/span><\/span><\/span><\/p>

The Company believes the engagement reflects increasing interest among U.S. maternal-fetal medicine practices in adopting patient-centric technologies that extend care beyond the clinic. Pulsenmore\u2019s solution combines home ultrasound with telehealth infrastructure, enabling clinicians to maintain clinical oversight while offering patients greater flexibility and continuity of care.<\/span><\/span><\/span><\/p>

TLC Perinatal is a specialized maternal-fetal medicine practice focused on diagnostic imaging and consultative care for pregnancies. Led by Medical Director Richard Broth, MD, the practice manages approximately 2,000 pregnancies annually across its two Maryland locations and is recognized for its progressive approach to integrating new technologies into prenatal care.<\/span><\/span><\/span><\/p>

\u00abPulsenmore\u2019s Home Ultrasound represents a vital step in expanding prenatal care access while enhancing convenience for all patients- it\u2019s a natural progression in our commitment to innovation. The device aligns with ACOG\u2019s 2025 Clinical Consensus by enabling remote monitoring of fetal health, personalizing care delivery, integrating patient preferences, and reducing office visits- all while maintaining or improving maternal and fetal outcomes through evidence-based practice.\u00bb said Dr. Richie Broth, Medical Director of TLC Perinatal.<\/span><\/span><\/span><\/p>

Dr. Elazar Sonnenschein, CEO of Pulsenmore, commented: \u201cAs we begin commercial operations in the United States, we are seeing strong engagement from practices that prioritize innovation and patient-centered care. Our collaboration with TLC Perinatal aims to demonstrate how maternal-fetal medicine teams can thoughtfully integrate home ultrasound into existing clinical workflows, offering patients greater flexibility while preserving physician oversight.\u201d<\/span><\/span><\/span><\/p>

\u00a0<\/h4>

About Pulsenmore
<\/strong>Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit <\/span>www.pulsenmore.com<\/span><\/a><\/u><\/span><\/span><\/span><\/p>


Forward-Looking Statements<\/span><\/span><\/span>
<\/strong>This press release contains forward-looking statements. In particular, statements using words such as \u201cmay,\u201d \u201cseek,\u201d \u201cwill,\u201d \u201cconsider,\u201d \u201clikely,\u201d \u201cassume,\u201d \u201cestimate,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201ccontemplate,\u201d \u201cdo not believe,\u201d \u201caim,\u201d \u201cgoal,\u201d \u201cdue,\u201d \u201cpredict,\u201d \u201cplan,\u201d \u201cproject,\u201d \u201ccontinue,\u201d \u201cpotential,\u201d \u201cpositioned,\u201d \u201cguidance,\u201d \u201cobjective,\u201d \u201coutlook,\u201d \u201ctrends,\u201d \u201cfuture,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201ctarget,\u201d \u201con track\u201d or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected outcome of Pulsenmore\u2019s engagement with TLC. Forward-looking statements reflect Pulsenmore\u2019s current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore\u2019s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company\u2019s lack of operating history; the Company\u2019s current and future capital requirements and the Company\u2019s belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company\u2019s ability to manufacture, market and sell its products and to generate revenues; the Company\u2019s ability to maintain its relationships with key partners and grow relationships with new partners; the Company\u2019s ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company\u2019s ability to launch and penetrate markets in new locations and new market segments; the Company\u2019s ability to retain key executive members and hire additional personnel; the Company\u2019s ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company\u2019s ability to achieve greater regulatory compliance needed in existing and new markets; the Company\u2019s ability to achieve key performance milestones in its planned operational testing; the Company\u2019s ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company\u2019s business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company\u2019s reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company\u2019s Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.<\/p>

\u00a0<\/p>

Investor Contact:<\/strong><\/p>

Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

OMER, Israel, Feb. 9, 2026 \/PRNewswire\/ \u2013 Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal […]<\/p>\n","protected":false},"author":4,"featured_media":58045,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":"","_links_to":"","_links_to_target":""},"categories":[39],"tags":[],"class_list":["post-58309","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"yoast_head":"\nPulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PULSENMORE | Home Ultrasound<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PULSENMORE | Home Ultrasound\" \/>\n<meta property=\"og:description\" content=\"OMER, Israel, Feb. 9, 2026 \/PRNewswire\/ \u2013 Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/\" \/>\n<meta property=\"og:site_name\" content=\"PULSENMORE | Home Ultrasound\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T11:38:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-31T09:42:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/pulsenmore.com\/wp-content\/uploads\/2026\/02\/Untitled-design-26-1024x576.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"576\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"hudi-webcart\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"hudi-webcart\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/\"},\"author\":\"AUTHOR\",\"headline\":\"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance\",\"datePublished\":\"2026-02-09T11:38:24+00:00\",\"dateModified\":\"2026-03-31T09:42:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/\"},\"wordCount\":927,\"publisher\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pulsenmore.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Untitled-design-26.png\",\"articleSection\":[\"Press releases\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/\",\"url\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/\",\"name\":\"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PULSENMORE | Home Ultrasound\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/pulsenmore.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Untitled-design-26.png\",\"datePublished\":\"2026-02-09T11:38:24+00:00\",\"dateModified\":\"2026-03-31T09:42:34+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/#primaryimage\",\"url\":\"https:\\\/\\\/pulsenmore.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Untitled-design-26.png\",\"contentUrl\":\"https:\\\/\\\/pulsenmore.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/Untitled-design-26.png\",\"width\":1920,\"height\":1080,\"caption\":\"Pulsenmore doctor\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/pulsenmore.com\\\/es\\\/home\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#website\",\"url\":\"https:\\\/\\\/pulsenmore.com\\\/\",\"name\":\"PULSENMORE | Home Ultrasound\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pulsenmore.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#organization\",\"name\":\"PULSENMORE | Home Ultrasound\",\"url\":\"https:\\\/\\\/pulsenmore.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/pulsenmore.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/home-ultrasound-logo.png\",\"contentUrl\":\"https:\\\/\\\/pulsenmore.com\\\/wp-content\\\/uploads\\\/2024\\\/05\\\/home-ultrasound-logo.png\",\"width\":470,\"height\":105,\"caption\":\"PULSENMORE | Home Ultrasound\"},\"image\":{\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#\\\/schema\\\/person\\\/93c0ed2dc5d299bf242e91b6dd185480\",\"name\":\"Rachel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g\",\"caption\":\"Rachel\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pulsenmore.com\\\/#\\\/schema\\\/person\\\/93c0ed2dc5d299bf242e91b6dd185480\",\"name\":\"Rachel\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g\",\"caption\":\"Rachel\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PULSENMORE | Home Ultrasound","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/","og_locale":"es_ES","og_type":"article","og_title":"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PULSENMORE | Home Ultrasound","og_description":"OMER, Israel, Feb. 9, 2026 \/PRNewswire\/ \u2013 Pulsenmore Ltd. (NASDAQ, TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal […]","og_url":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/","og_site_name":"PULSENMORE | Home Ultrasound","article_published_time":"2026-02-09T11:38:24+00:00","article_modified_time":"2026-03-31T09:42:34+00:00","og_image":[{"width":1024,"height":576,"url":"https:\/\/pulsenmore.com\/wp-content\/uploads\/2026\/02\/Untitled-design-26-1024x576.png","type":"image\/png"}],"author":"hudi-webcart","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"hudi-webcart","Tiempo de lectura":"5 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/#article","isPartOf":{"@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/"},"author":"AUTHOR","headline":"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance","datePublished":"2026-02-09T11:38:24+00:00","dateModified":"2026-03-31T09:42:34+00:00","mainEntityOfPage":{"@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/"},"wordCount":927,"publisher":{"@id":"https:\/\/pulsenmore.com\/#organization"},"image":{"@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/#primaryimage"},"thumbnailUrl":"https:\/\/pulsenmore.com\/wp-content\/uploads\/2026\/02\/Untitled-design-26.png","articleSection":["Press releases"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/","url":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/","name":"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance - PULSENMORE | Home Ultrasound","isPartOf":{"@id":"https:\/\/pulsenmore.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/#primaryimage"},"image":{"@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/#primaryimage"},"thumbnailUrl":"https:\/\/pulsenmore.com\/wp-content\/uploads\/2026\/02\/Untitled-design-26.png","datePublished":"2026-02-09T11:38:24+00:00","dateModified":"2026-03-31T09:42:34+00:00","breadcrumb":{"@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/#primaryimage","url":"https:\/\/pulsenmore.com\/wp-content\/uploads\/2026\/02\/Untitled-design-26.png","contentUrl":"https:\/\/pulsenmore.com\/wp-content\/uploads\/2026\/02\/Untitled-design-26.png","width":1920,"height":1080,"caption":"Pulsenmore doctor"},{"@type":"BreadcrumbList","@id":"https:\/\/pulsenmore.com\/pulsenmore-builds-u-s-momentum-with-another-commercial-engagement-following-fda-clearance\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pulsenmore.com\/es\/home\/"},{"@type":"ListItem","position":2,"name":"Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance"}]},{"@type":"WebSite","@id":"https:\/\/pulsenmore.com\/#website","url":"https:\/\/pulsenmore.com\/","name":"PULSENMORE | Home Ultrasound","description":"","publisher":{"@id":"https:\/\/pulsenmore.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pulsenmore.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/pulsenmore.com\/#organization","name":"PULSENMORE | Home Ultrasound","url":"https:\/\/pulsenmore.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/pulsenmore.com\/#\/schema\/logo\/image\/","url":"https:\/\/pulsenmore.com\/wp-content\/uploads\/2024\/05\/home-ultrasound-logo.png","contentUrl":"https:\/\/pulsenmore.com\/wp-content\/uploads\/2024\/05\/home-ultrasound-logo.png","width":470,"height":105,"caption":"PULSENMORE | Home Ultrasound"},"image":{"@id":"https:\/\/pulsenmore.com\/#\/schema\/logo\/image\/"}},{"@type":["Person","Organization"],"@id":"https:\/\/pulsenmore.com\/#\/schema\/person\/93c0ed2dc5d299bf242e91b6dd185480","name":"Rachel","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g","caption":"Rachel"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g"}},{"@type":"Person","@id":"https:\/\/pulsenmore.com\/#\/schema\/person\/93c0ed2dc5d299bf242e91b6dd185480","name":"Rachel","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7ea5266b17c60e8e8ad1cdfe6a6c6805aa183a25b516795250709863b9082f19?s=96&d=mm&r=g","caption":"Rachel"}}]}},"_links":{"self":[{"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/posts\/58309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/comments?post=58309"}],"version-history":[{"count":10,"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/posts\/58309\/revisions"}],"predecessor-version":[{"id":58858,"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/posts\/58309\/revisions\/58858"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/media\/58045"}],"wp:attachment":[{"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/media?parent=58309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/categories?post=58309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pulsenmore.com\/es\/wp-json\/wp\/v2\/tags?post=58309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}